title: Effect of estrogen-progestin hormonal replacement therapy on plasma antithrombin III of postmenopausal women.
abstract: BACKGROUND
  This study was performed to evaluate antithrombin III levels in postmenopausal women receiving hormonal replacement treatment.
  
  
  METHODS
  It is a prospective randomized study concerning 19 postmenopausal patients, aged 40 to 65 years, who received either continuous daily oral equine conjugated estrogen 0.625 mg (group A, N=10) or daily transdermal 17beta-estradiol 50 microg (group B, N=9). Medroxyprogesterone acetate (5 mg/day, 14 days monthly) was given to all patients. Blood samples were obtained before and after 3, 6, 9 and 12 months of treatment. Coagulation tests included Antithrombin III (functional method), prothrombin time, partial activated prothrombin time, thrombin time, factor V, fibrinogen, platelet count and euglobulin lysis time. Friedman analysis of variance and Mann-Whitney test were used for statistical analysis.
  
  
  RESULTS
  Antithrombin III level was reduced (p<0.05) in group A but not in group B, although it remained within normal range. No changes were detected in the other coagulation tests.
  
  
  CONCLUSIONS
  These data suggest that oral conjugated estrogen replacement reduces functional ATIII, whereas transdermal estradiol replacement therapy does not modify it.
authors.affiliation: Division of Endocrinological Gynecology and Climacterium, Universidade Federal de São Paulo, Brazil.
authors.forename: C E
authors.initials: CE
authors.lastname: Bonduki
authors.forename: D M
authors.initials: DM
authors.lastname: Lourenço
authors.forename: E
authors.initials: E
authors.lastname: Baracat
authors.forename: M
authors.initials: M
authors.lastname: Haidar
authors.forename: M A
authors.initials: MA
authors.lastname: Noguti
authors.forename: E L
authors.initials: EL
authors.lastname: da Motta
authors.forename: G R
authors.initials: GR
authors.lastname: Lima
mesh_terms: D000279:Administration, Cutaneous; D000284:Administration, Oral; D000328:Adult; D000990:Antithrombin III / Q000032:analysis* / Q000187:drug effects; D015331:Cohort Studies; D004958:Estradiol / Q000008:administration & dosage / Q000494:pharmacology*; D015914:Estrogen Replacement Therapy / Q000379:methods*; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000494:pharmacology; D008875:Middle Aged; D017698:Postmenopause / Q000097:blood* / Q000187:drug effects; D045167:Progesterone Congeners / Q000008:administration & dosage / Q000494:pharmacology; D011446:Prospective Studies
chemical_list: D004966:Estrogens, Conjugated (USP); D045167:Progesterone Congeners; D004958:Estradiol; D000990:Antithrombin III; D008525:Medroxyprogesterone